Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
The interaction of secreted phospholipase A2-IIA with the microbiota alters its lipidome and promotes inflammation
Etienne Doré, … , Arnaud Droit, Eric Boilard
Etienne Doré, … , Arnaud Droit, Eric Boilard
Published January 25, 2022
Citation Information: JCI Insight. 2022;7(2):e152638. https://doi.org/10.1172/jci.insight.152638.
View: Text | PDF
Research Article Inflammation Microbiology

The interaction of secreted phospholipase A2-IIA with the microbiota alters its lipidome and promotes inflammation

  • Text
  • PDF
Abstract

Secreted phospholipase A2-IIA (sPLA2-IIA) hydrolyzes phospholipids to liberate lysophospholipids and fatty acids. Given its poor activity toward eukaryotic cell membranes, its role in the generation of proinflammatory lipid mediators is unclear. Conversely, sPLA2-IIA efficiently hydrolyzes bacterial membranes. Here, we show that sPLA2-IIA affects the immune system by acting on the intestinal microbial flora. Using mice overexpressing transgene-driven human sPLA2-IIA, we found that the intestinal microbiota was critical for both induction of an immune phenotype and promotion of inflammatory arthritis. The expression of sPLA2-IIA led to alterations of the intestinal microbiota composition, but housing in a more stringent pathogen-free facility revealed that its expression could affect the immune system in the absence of changes to the composition of this flora. In contrast, untargeted lipidomic analysis focusing on bacteria-derived lipid mediators revealed that sPLA2-IIA could profoundly alter the fecal lipidome. The data suggest that a singular protein, sPLA2-IIA, produces systemic effects on the immune system through its activity on the microbiota and its lipidome.

Authors

Etienne Doré, Charles Joly-Beauparlant, Satoshi Morozumi, Alban Mathieu, Tania Lévesque, Isabelle Allaeys, Anne-Claire Duchez, Nathalie Cloutier, Mickaël Leclercq, Antoine Bodein, Christine Payré, Cyril Martin, Agnes Petit-Paitel, Michael H. Gelb, Manu Rangachari, Makoto Murakami, Laetitia Davidovic, Nicolas Flamand, Makoto Arita, Gérard Lambeau, Arnaud Droit, Eric Boilard

×

Figure 8

Identification of the expression of sPLA2-IIA using its fecal lipid signature.

Options: View larger image (or click on image) Download as PowerPoint
Identification of the expression of sPLA2-IIA using its fecal lipid sign...
Machine learning was used to generate a fecal lipid signature able to distinguish WT and sPLA2-IIATGN mice independently of their housing facility and sex (n = 15–16 nonarthritic WT and sPLA2-IIATGN mice housed in either the SPF or Elite animal facility for 8 or 14 months, respectively). (A) Visualization of the data distribution using the identified lipids by PCA with 99% confidence ellipses to confirm the discrimination between the groups. (B) Heatmap of the Z scores — i.e., the number of SD above or below the mean, calculated from the concentration of the lipids. (C) Concentration of the 8 identified lipid metabolites in fecal samples. DAG, diacylglycerol; TAG, triacylglycerol; FA, fatty acid. Data are presented as boxes representing the median and quartiles, with whiskers extending up to 1.5 interquartile range. Statistical analysis included unpaired t test. **P < 0.01, ***P < 0.001.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts